Oruka Therapeutics (ORKA) Net Cash Flow Growth (1y) (2011 - 2026)
Oruka Therapeutics (ORKA) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn | 53.46% |
| 10 | Oruka Therapeutics | 949.16 Mn | 118.01 Mn | - | -88.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -88.25% |
| Dec 31, 2025 | 87.31% |
| Sep 30, 2025 | -93.46% |
| Jun 30, 2025 | -44.87% |
| Mar 31, 2025 | -20.71% |
| Dec 31, 2024 | -32,977.65% |
| Sep 30, 2024 | 23,812.04% |
| Jun 30, 2024 | -1,718.73% |
| Mar 31, 2024 | 1,839.37% |
| Dec 31, 2023 | 29.32% |
| Sep 30, 2023 | 33.19% |
| Jun 30, 2023 | 73.53% |
| Mar 31, 2023 | 62.91% |
| Dec 31, 2022 | 69.84% |
| Sep 30, 2022 | 48.85% |
| Jun 30, 2022 | 29.82% |
| Mar 31, 2022 | -124.07% |
| Dec 31, 2021 | -144.76% |
| Sep 30, 2021 | -112.19% |
| Jun 30, 2021 | -257.51% |